MCM
NBIX icon

Moore Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Moore Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-150,000
Closed -$16.9M – 504
2023
Q3 		$16.9M Buy
+150,000
New +$15.8M 0.31% 62

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Moore Capital Management's NBIX Position: Q3 2024 in Review

Moore Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 40,000 shares — an estimated $5.51M sold.

Moore Capital Management first reported a position in NBIX in Q2 2015 and held it in 8 quarters. The position peaked at $9.21M in Q4 2020. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Moore Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Moore Capital Management sold 40,000 Neurocrine Biosciences shares in Q3 2024, an estimated $5.51M.
  • Moore Capital Management first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 8 quarters.
  • Moore Capital Management's Neurocrine Biosciences position peaked at $9.21M in Q4 2020.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Moore Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.